NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE: ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN. Investigation Details On August 6, 2024, Enfusion reported its financial results for the second quarter of 2024. The Compa ...

Alistair Berg Investment overview I wrote about Enfusion (NYSE:ENFN) previously (late March this year) with a buy rating, as the growth outlook remained positive and was well-supported by good execution. I remain buy-rated for ENFN as I liked the execution that management is demonstrating so far, specifically in winning new customers in launch markets and penetrating the upmarket. The current hurdle to growth acceleration seems to be a macro problem that should recover in due time. 2Q24 earnings (announced ...

Enfusion, Inc. (NYSE:ENFN) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Bill Wright - Head, IR Oleg Movchan - CEO Bradley Herring - CFO Neal Pawar - COO Conference Call Participants Michael Infante - Morgan Stanley Faith Brunner - William Blair Gabriela Borges - Goldman Sachs Alexei Gogolev - JPMorgan Matthew Kikkert - Stifel Operator Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to Enfusion Second Quarter 2024 Earnings Conference Call. At this t ...

NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE: ENFN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Enfusion and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On or around October 21, 20 ...

Table of Contents Title of each class Trading symbol Name of Exchange on which registered Class A common stock, par value $0.001 per share ENFN New York Stock Exchange UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition per ...

Enfusion, Inc. (ENFN) reported $49.46 million in revenue for the quarter ended June 2024, representing a yearover-year increase of 15.8%. EPS of $0.05 for the same period compares to $0.04 a year ago. The reported revenue represents a surprise of -1.61% over the Zacks Consensus Estimate of $50.27 million. With the consensus EPS estimate being $0.06, the EPS surprise was -16.67%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to deter ...

Enfusion, Inc. (ENFN) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -16.67%. A quarter ago, it was expected that this company would post earnings of $0.04 per share when it actually produced earnings of $0.06, delivering a surprise of 50%. Over the last four quarters, the company h ...

Exhibit 99.1 o ore hoto the color of one of one of one of one of one o @ or of or of or or of of of the for of Or of of of on of of on on of o t to to to to . ● . . Enfusion 2Q 2024 Shareholder Letter ``. .. August 2024 . . . 0 0 0 0 ·· 0000000 0 0 0 0 0 . . . o o o o o o o o 0 0 enfusion Disclaimer Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward- looking within the meaning of Section 27A of the Securities Ac ...

Enfusion, Inc. (NYSE:ENFN) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Bill Wright - Head, Investor Relations Oleg Movchan - Chief Executive Officer Brad Herring - Chief Financial Officer Neal Pawar - Chief Operating Officer Conference Call Participants Michael Infante - Morgan Stanley Faith Brunner - William Blair Jeffrey Lane - Stifel Kevin McVeigh - UBS Alexei Gogolev - JPMorgan Gabriela Borges - Goldman Sachs Koji Ikeda - Bank of America Operator Good morning, ladies and ...

Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40949 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdic ...